阳光诺和：获得《药物临床试验批准通知书》

每日经济新闻07-11

每经AI快讯，阳光诺和（SH 688621，收盘价：42.64元）7月11日晚间发布公告称，近日，全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目“STC008注射液”的临床试验申请获得批准。2023年1至12月份，阳光诺和的营业收入构成为：CRO业务占比99.88%。截至发稿，阳光诺和市值为48亿元。道达号（daoda1997）“个股...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2450215336?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-11 17:12","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2450215336","market":"sh","top_or_hot":-1,"title":"阳光诺和：获得《药物临床试验批准通知书》","media":"每日经济新闻","content":"<div>\n<p>每经AI快讯，阳光诺和（SH 688621，收盘价：42.64元）7月11日晚间发布公告称，近日，全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目“STC008注射液”的临床试验申请获得批准。2023年1至12月份，阳光诺和的营业收入构成为：CRO业务占比99.88%。截至发稿，阳光诺和市值为48亿元。道达号（daoda1997）“个股...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071117143895a5249e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阳光诺和：获得《药物临床试验批准通知书》</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阳光诺和：获得《药物临床试验批准通知书》\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-11 17:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071117143895a5249e&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>每经AI快讯，阳光诺和（SH 688621，收盘价：42.64元）7月11日晚间发布公告称，近日，全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目“STC008注射液”的临床试验申请获得批准。2023年1至12月份，阳光诺和的营业收入构成为：CRO业务占比99.88%。截至发稿，阳光诺和市值为48亿元。道达号（daoda1997）“个股...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071117143895a5249e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688621","symbol_name":"阳光诺和","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071117143895a5249e&s=b","article_id":"2450215336","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071117143895a5249e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2450215336","pubTimestamp":1720689145,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"每经AI快讯，阳光诺和 7月11日晚间发布公告称，近日，全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目“STC008注射液”的临床试验申请获得批准。2023年1至12月份，阳光诺和的营业收入构成为：CRO业务占比99.88%。截至发稿，阳光诺和市值为48亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688621":"阳光诺和","BK0216":"研究试验"},"translate_title":"Sunshine Novo: Obtained the \"Notice of Drug Clinical Trial Approval\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688621":1},"content_text":"每经AI快讯，阳光诺和（SH 688621，收盘价：42.64元）7月11日晚间发布公告称，近日，全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目“STC008注射液”的临床试验申请获得批准。2023年1至12月份，阳光诺和的营业收入构成为：CRO业务占比99.88%。截至发稿，阳光诺和市值为48亿元。道达号（daoda1997）“个股趋势”提醒：1. 阳光诺和近30日内北向资金持股量增加11.80万股，占流通股比例减少0.03%；2. 近30日内无机构对阳光诺和进行调研。每经头条（nbdtoutiao）——预算数千万，地标广场却被吐槽“更新了个寂寞”！市民称“跑道褪色、草坪还是原来的”，项目中标者都是谁？陕西榆林：彻底调查！(记者 蔡鼎)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450215336"}